%0 Journal Article
%A Scuteri, Damiana
%A Tonin, Paolo
%A Nicotera, Pierluigi
%A Vulnera, Marilù
%A Altieri, Giuseppina Cristina
%A Tarsitano, Assunta
%A Bagetta, Giacinto
%A Corasaniti, Maria Tiziana
%T Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine.
%J Toxins
%V 14
%N 8
%@ 2072-6651
%C Basel
%I MDPI
%M DZNE-2022-01439
%P 529
%D 2022
%Z CC BY: https://creativecommons.org/licenses/by/4.0/
%X OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two decades for chronic migraine prevention. The recently approved monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) pathway open a new age for chronic migraine control. However, some 40
%K Antibodies, Monoclonal: therapeutic use
%K Botulinum Toxins, Type A: therapeutic use
%K Calcitonin Gene-Related Peptide: antagonists & inhibitors
%K Drug Therapy, Combination: adverse effects
%K Humans
%K Migraine Disorders: prevention & control
%K Treatment Outcome
%K PRISMA 2020 (Other)
%K anti-CGRP monoclonal antibodies (Other)
%K migraine (Other)
%K onabotulinumtoxinA (Other)
%K pooled analysis (Other)
%K Antibodies, Monoclonal (NLM Chemicals)
%K Botulinum Toxins, Type A (NLM Chemicals)
%K Calcitonin Gene-Related Peptide (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36006191
%2 pmc:PMC9413678
%R 10.3390/toxins14080529
%U https://pub.dzne.de/record/165134